Halozyme Therapeutics HALO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $595.49M+51.7% | $557.28M+65.2% | $485.36M+52.2% | ||
| $12.93M+22.6% | $11.39M+10.6% | $10.74M+1.6% | $10.64M-0.3% | $10.54M-3.1% | ||
| $57.53M+30.2% | $51.57M+18.9% | $46.46M+11.7% | $46.87M+22.1% | $44.18M+14.7% | ||
| $677.42M+34.4% | $651.56M+36.0% | $611M+51.6% | $547.78M+30.4% | $503.86M+16.9% | ||
| $9.76M+20.5% | $6.97M-34.8% | $8.6M-16.1% | $7.08M-39.3% | $8.1M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$571.1M-157% | -$530.14M— | -$221.69M— | ||
| —— | —— | $265.35M+321% | -$126M-278% | $11.7M— | ||
| $667.65M+34.7% | $644.59M+37.6% | $602.4M+53.4% | $540.69M+32.4% | $495.76M+17.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
